Clinical trial
Phase II Study of Epirubicin and Rituximab in Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma and CLL
NCT00062296 is registered in ClinicalTrials.gov with Fox Chase Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Study of Epirubicin and Rituximab in Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma and CLL
- Lead sponsor
- Fox Chase Cancer Center
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 31, 2003
- Completion date
- August 31, 2005
- Enrollment
- 5 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.